Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to fight tough gynecological cancers

NCT ID NCT06906341

Recruiting now Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests a drug called relacorilant, taken as a pill, combined with two standard chemotherapy drugs (nab-paclitaxel and bevacizumab) in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to see if the combination can slow cancer growth or shrink tumors. About 270 participants will join this global Phase 2 trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
relacorilant (a drug taken by mouth) combined with nab-paclitaxel and bevacizumab (given by IV)
What this could lead to
If successful, this could provide a new treatment option for people with certain gynecological cancers that have stopped responding to standard therapies.
What could go wrong
This is an early Phase 2 trial with a small number of participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm fallopian tube cancer fallopian tube carcinoma fallopian tube disorder fallopian tube neoplasm female reproductive system neoplasm neoplasm Neoplasms by Site ovarian cancer ovarian carcinoma ovarian disorder peritoneal neoplasm primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER FALLOPIAN TUBE CANCER OVARIAN CANCER PERITONEAL NEOPLASMS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 004

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • 014

    RECRUITING

    San Francisco, California, 94143, United States

  • 108

    RECRUITING

    Leuven, 3000, Belgium

  • 114

    RECRUITING

    Madrid, 28034, Spain

  • 115

    RECRUITING

    Barcelona, 08035, Spain

  • 121

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • 122

    RECRUITING

    Milan, 20141, Italy

  • 124

    RECRUITING

    Rome, 00168, Italy

  • 127

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • 150

    RECRUITING

    Palo Alto, California, 94304, United States

  • 255

    RECRUITING

    Berlin, 10117, Germany

  • 292

    RECRUITING

    Albuquerque, New Mexico, 97102, United States

  • 293

    RECRUITING

    Torino, 10128, Italy

  • 295

    RECRUITING

    Pavia, 27100, Italy

  • 300

    RECRUITING

    Norfolk, Virginia, 23502, United States

  • 304

    RECRUITING

    Centerville, Ohio, 45459, United States

  • 306

    RECRUITING

    Lille, 59000, France

  • 307

    RECRUITING

    Nancy, 54100, France

  • 308

    RECRUITING

    Toulouse, 31059, France

  • 310

    RECRUITING

    Nice, 06100, France

  • 319

    RECRUITING

    Treviso, 31100, Italy

  • 321

    RECRUITING

    Catania, 95126, Italy

  • 323

    RECRUITING

    Plérin, 22190, France

  • 324

    RECRUITING

    Pierre-Bénite, 69495, France

  • 325

    RECRUITING

    Hasselt, 3500, Belgium

  • 326

    RECRUITING

    Charleroi, 6000, Belgium

  • 328

    RECRUITING

    Aalst, Belgium, 9300, Belgium

  • 329

    RECRUITING

    Siedlce, 08-MO, Poland

  • 330

    RECRUITING

    Valencia, 46026, Spain

  • 334

    RECRUITING

    Kansas City, Missouri, 64132, United States

  • 335

    RECRUITING

    Miami Beach, Florida, 33140, United States

  • 341

    RECRUITING

    Gdynia, 81-519, Poland

  • 349

    RECRUITING

    Badalona, 08916, Spain

  • 396

    RECRUITING

    Seoul, Gangnam-gu, 06351, South Korea

  • 397

    RECRUITING

    Gyeonggi-do, Goyang-si, 10408, South Korea

  • 398

    RECRUITING

    Seoul, Seodaemun-gu, 03722, South Korea

  • 399

    RECRUITING

    Seoul, Jongno-gu, 03080, South Korea

  • 403

    RECRUITING

    Seoul, Songpa-gu, 05505, South Korea

  • 516

    RECRUITING

    Milan, 20159, Italy

  • 517

    RECRUITING

    Eugene, Oregon, 97401, United States

  • 518

    RECRUITING

    Minneapolis, Minnesota, 55404, United States

  • 519

    RECRUITING

    Aachen, 52074, Germany

  • 520

    RECRUITING

    Kempten, 87439, Germany

  • 521

    RECRUITING

    St Louis, Missouri, 63110, United States

  • 522

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • 523

    RECRUITING

    Seoul, Seocho-gu, 06591, South Korea

  • 543

    RECRUITING

    West Palm Beach, Florida, 33041, United States

  • 544

    RECRUITING

    Fort Myers, Florida, 33901, United States

  • 558

    RECRUITING

    Valencia, 46010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.